Targeting proteins involved in cancer pathways has become a cornerstone of modern cancer therapy. Monoclonal antibodies are designed to target specific proteins on the surface of cancer cells. For instance, trastuzumab (Herceptin) is a monoclonal antibody that targets the HER2 protein in HER2-positive breast cancer. Additionally, tyrosine kinase inhibitors (TKIs) like imatinib (Gleevec) inhibit the activity of specific enzymes crucial for cancer cell survival and proliferation.
